Back to News
Market Impact: 0.42
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Source: zacks.com
Healthcare & Biotech
Amgen's dazodalibep met the primary endpoint in a Phase III study for systemic Sjogren's disease, demonstrating sustained improvement in disease activity through week 48. The positive late-stage data materially de-risks the program and supports a potential regulatory filing and future commercial opportunity in Sjogren's disease.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
AMGN0.82
More News
- Amgen price target raised by Jefferies to $410 after positive Sjögren's data
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Australia says OpenAI agent hacked Medicare portal
- US aviation sanctions disrupt Iran flights, push travellers overland
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’